Delcath Systems Inc.

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

regional chemotherapy · Oncology
Regional chemotherapy involves delivering high doses of chemotherapy directly to a specific area of the body, such as the liver, to treat cancer.

Phase 2 pipeline

Cisplatin and Gemcitabine · Oncology
Cisplatin is a platinum-based alkylating agent that cross-links DNA, thereby inhibiting DNA replication and transcription. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by causing DNA strand breaks.
Trifluridine-tipiracil plus Bevacizumab Alone

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Delcath Systems Inc.

What is Delcath Systems Inc.'s pipeline?

Delcath Systems Inc. has 1 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include regional chemotherapy.

Sector hub: All tracked pharma companies